DiaVacs

About:

DiaVacs is a developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependence

Website: https://www.diavacs.com

Description:

The company potentially addresses the disadvantages of prior approaches by offering local antigen-specific immunosuppression, halting the pathogenic autoimmune response without compromising the body's immune system, and complements emerging regenerative approaches by protecting newly created beta cells from autoimmune attack, enabling patients to get rid from lifelong dependency on insulin.

Total Funding Amount:

$850000

Headquarters Location:

Edgewater, New Jersey, United States

Founded Date:

2013-01-01

Founders:

Dietrich Stephan, Haro Hartounian, Nick Giannoukakis

Number of Employees:

51-100

Last Funding Date:

2015-03-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai